Nanqun is Director of DMPK and is responsible for all DMPK related activities. Prior to joining Avilar, Nanqun had 19 years of R&D experience in small molecules or peptides, covering the areas of immunology, oncology, infectious and genetic diseases. With increasing roles at Ra Pharmaceuticals, Ignyta, Ardea Biosciences, Genzyme/Sanofi and Valeant Pharmaceuticals, he contributed to the advancing of multiple drug candidates from early discovery to clinical development, and the approval of 4 marketed medicines, including plerixafor, eligustat, lesinurad and entrectinib. Nanqun is a co-author of over 40 peer-reviewed journal articles or book chapters. He obtained his PhD in Food Science from Rutgers, the State University of New Jersey.
